Главная страница

Newswire
Stock Indexes
Exrate
Equities
Analysis


About AK&M
Services
Site Map
Support

News ServiceForexMarket AnalysisProducts and Services
26/12/2013
11:29
M&A: J.P. Morgan Chase & Co buys indirect 5.22% stake in Veropharm

J.P. Morgan Chase & Co acquired indirect ownership of 5.22% of the shares in OAO Veropharm, Veropharm informed.

J.P. Morgan Chase & Co acquired this ownership on December 19, 2013.

J.P. Morgan Chase & Co is the controlling shareholder of J.P. Morgan Asset Management Holdings Inc. which itself is the controlling shareholder of J.P. Morgan Investment Management Inc and J.P. Morgan Asset Management International Limited. J.P. Morgan Asset Management International Limited is the controlling shareholder of J.P. Morgan Asset Management Holdings (UK) Limited, the controlling shareholder of J.P. Morgan Asset Management (UK) Limited.

OAO Veropharm (tax number: 7725081786) is a Russian pharmaceutical company with production facilities located in Belgorod, Voronezh, and Pokrov. Veropharm's authorized capital is RUB 10 million. The company's product range contains over 300 medicinal products.

IFRS net profit of Veropharm for H1 2013, according to the company's unaudited statement, dropped by 36.3% to RUB 499.4 million from RUB 783 million for the same period in 2012. Revenue decreased by 24.5% to RUB 2.392 billion from RUB 3.169 billion, EBITDA was RUB 717.2 million, EBITDA margin was 30%.

According to the information and retrieval system DataCapital, RAS net loss of Veropharm for H1 2013 was RUB 57.749 million against a net profit of RUB 255.322 million for H1 2012. Revenue decreased by 28.2% to RUB 1.223 billion from RUB 1.704 billion.


"AK&M", 26.12.2013

 

Free trial for a week.

TopList Rambler's Top100 Rambler's Top100


CONTACT INFORMATION


Tel: (7-495) 916-70-30 / 71-51
        (7-495) 132-61-76 / 61-73
Fax: (7-495) 132-69-18 / 60-93
        (7-495) 916-71-64 / 70-71
e-mail: postmail@akm.ru
Copyright © 1996-2008 AK&М